BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210613
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T190338
CREATED:20210401T075326Z
LAST-MODIFIED:20210401T075326Z
UID:29614-1623542400-1623801599@www.pharmajournalist.com
SUMMARY:9th PREDiCT: Tumor Models Cell Therapy Summit
DESCRIPTION:With commitments to advancing your preclinical and translational oncology research\, we are delighted to bring the 9th annual PREDiCT: Tumor Models Cell Therapy Summit to your screens in July. \nSee best-in-class tumor models and how they can be effectively utilized to model the tumor microenvironment and further your MoA understanding for new cell therapies. \nLearn to improve your translational and clinical confidence through the use of models to answer critical safety and efficacy questions\, predict toxicity and optimize dosing for patients. \nWhether you work in early discovery or late development\, there is something for all non-clinical professionals with two dedicated tracks: one focused on preclinical modelling and one looking at translational studies. \nBelow are a few highlights you won’t want to miss! \n\nNovartisshare how to use a simple xenograft model to effectively assess CAR-T efficacy\nAstraZenecashows how to guide innovative clinical trials for cell therapies using preclinical data\nTakedadiscuss how to leverage single-cell analytics to understand the complexities of the tumor microenvironment\nHarvard Medical Schoolshare how they use multiple tumor models to advance NK cell therapies\n\nGet involved! Our scientific poster sessions will be returning this year so you can share your latest advances and be apart of the conversation. \nTo know more about 9th PREDiCT: Tumor Models Cell Therapy Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-predict-tumor-models-cell-therapy-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210614
DTEND;VALUE=DATE:20210616
DTSTAMP:20260515T190338
CREATED:20190206T211230Z
LAST-MODIFIED:20200330T122307Z
UID:19393-1623628800-1623801599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SMi are proud to announce the 5th annual conference:\nPre-Filled Syringes West Coast 2020\n14-15 June 2021\nSan Diego\, CA\, USA\nHyatt Regency Mission Bay\nwww.prefilled-syringes-westcoast.com/pjwl \nAssessing Device Development and Regulation for Advanced Innovation \nSMi is proud to present the 5th Annual Pre-Filled Syringes West Coast Conference in San Diego on 14th and 15th June 2021. \n \nFollowing the success of the last event\, the Pre-Filled Syringes West Coast conference is back to uncover the latest innovations in combination product development\, device design\, human factors engineering and drug product formulation to give a holistic overview of the industry and what we can expect for the future. \nWith the global market for prefilled syringes estimated to exceed $9.7bn by 2025\, this year’s agenda will encompass key drivers and hot topics of the industry including; updates to regulatory guidance from industry experts and regulatory bodies\, case studies on device design and complex formulation\, life cycle and control strategies\, and innovations in connectivity and digital health. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nPLUS\, two interactive post conference workshops: \nWorkshop A: Connected devices and digital health: How to navigate the US FDA usability engineering requirements\nHosted by Shannon Clark\, Principal\, UserWise\, Inc. \nWorkshop B: Postmarket safety reporting: The current regulatory environment with a global impact\nHosted by Khaudeja Bano\, Sr. Medical Director\, Abbott Molecular  \nKey Reasons to Attend: \n\nEngage in case study presentations from leading pharma and biotech companies on complex product formulation and optimising device design to aid delivery\nDiscuss show to optimise current processes to align with global regulatory updates\nDelve into human factors engineering best practices\nUncover how industry is incorporating connectivity and digital health to optimise the user experience \n\nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers \n\nEarly bird deadlines: \n\nRegister by 28th February to save $400\nRegister by 31st March to save $200\nRegister by 30th April to save $100\n\n\nTo register or for more information visit: www.prefilled-syringes-westcoast.com/pjwl \nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast/
LOCATION:Hyatt Regency Mission Bay\, 1441 Quivira Road\, San Diego\, CA\, 92109\, United States
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210615
DTEND;VALUE=DATE:20210618
DTSTAMP:20260515T190338
CREATED:20210212T080535Z
LAST-MODIFIED:20210212T080535Z
UID:28924-1623715200-1623974399@www.pharmajournalist.com
SUMMARY:2nd RNAi-Based Therapeutics – Digital Summit
DESCRIPTION:As investments and collaborations hit a record high\, the RNAi therapeutics industry continues to rapidly expand. With RNAi drugs prevailing as a therapy with huge potential against liver diseases\, exciting efforts have now turned to a wide range of other diseases\, from CNS\, oncology\, metabolism and more. Despite the growing momentum\, much needs to be addressed in terms of targeted delivery\, safety\, and efficiency to fully unleash the therapeutic value of RNAi drugs. \n \nBuilt with large pharma and pioneering biotech insights\, the 2nd RNAi- Based Therapeutics Summit returns virtually in 2021 to reunite key stakeholders of the field to tap into the full therapeutic opportunity of a wide-range of targeted RNAi therapies with enhanced endosomal escape\, extrahepatic delivery\, & PKPD for CNS\, oncology & beyond. \nWith a number of RNAi based clinical candidates emerging and excitement building in the field\, join the 2nd RNAi Based Therapeutic Summit 2021 – the comprehensive industry guide for senior biopharmaceutical leaders from discovery\, translation & clinical development functions to stay ahead of the race in developing the first targeted extrahepatic RNAi therapy that addresses unmet patient need. \nTo know more about 2nd RNAi-Based Therapeutics please click here.
URL:https://www.pharmajournalist.com/event/2nd-rnai-based-therapeutics-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR